Pradeep Garg, PhD

Executive Director
Center for Molecular Imaging and Therapy
Biomedical Research Foundation of Northwest Louisiana
1505 Kings Highway
Shreveport, LA 71103, USA


Dr.Garg, PhD is the Executive Director of “Center for Molecular Imaging and Therapy” (CMIT), a subsidiary of Biomedical Research Foundation of Northwest Louisiana, Shreveport, LA (BRF). Prior to his joining BRF, Dr. Garg was Professor of Radiological Sciences and Director of PET research Center at Wake Forest University School of Medicine, Winston Salem, NC, USA. Prior to Wake Forest University Health Sciences, Dr. Garg worked at Duke University Medical Center (1987-1995) and then moved as a faculty in the Department of Radiology at Yale University Medical Center, New Haven, CT (1995-2003) where he later became the Director of the Yale University PET Center.
Dr. Garg is a Molecular Imaging Scientist with research focus in the development and evaluation of novel radiopharmaceuticals as diagnostic and/or therapeutic agents. One of the major strength of his research is his ability to carry out research from bench to bedside. His research focus could be categorized into three major focus areas viz. Oncology, Cardiac and Neurobiology studies. His laboratory has developed novel methods to incorporate bioactive functional groups and radionuclides into a variety of small molecules of biological interest, monoclonal antibodies, single chain proteins, peptides, and amino acids. He participated in multiple clinical trials that ranged from studying imaging probes as tool to monitor therapeutic efficacy in patient, assessing prognostic value of molecular imaging probes in patients with cancers such as prostate and esophageal cancer, to early diagnosis of Alzheimer disease. His group has been very active in developing imaging probes for a variety of neurological dysfunctions and has extensive work experience interrogating dopaminergic, serotonergic and norepinephrine systems. His research collaborators include basic science researchers as well as clinicians and clinical researchers.
He has published extensively in national and international journals. He served on numerous national and international committees. He is a member of several professional organizations such as Society of Nuclear Medicine and Molecular Imaging, Society of Radiopharmaceutical Sciences, American Chemical Society, and American Association for Cancer Research. He served as Board member and as President of the Radiopharmaceutical Science Council of the Society of Nuclear Medicine and Molecular Imaging. He is on editorial board of several journals and is an active reviewer for a variety of national and international journals.

Research Interest

His research interests include: radiology, imaging, animals, whole, basic mechanisms, clinical trials, immunology, allergy, inflammation, nuclear medicine, reproductive system, animals, cells, membranes, tissue, cancer, oncogenesis, human, adult, technology, technique development, translational research

Scientific Activities


• Annual Meeting Abstract Reviewer- (2003 – Present)
• Sub-chair Scientific Review Committee- (2002-Present)


Society of Nuclear Medicine
• Radiological Society of North America
• Society of Radiopharmaceutical Chemistry
• American Association of Cancer Research
• American Chemical Society


1. Varma RS, Garg PK. 5-chloro-3-arylthiosemicarbazono-2-indolinoes as antimicrobial agents. Acta Pharm Yugoslavica. 1980; 30:199-204. doi:
2. Varma RS, Garg PK. 3-arylglycylhydrazono-2-indolinones as antibacterial agents. Indian J Pharm Sci. 1981; 43:8-11. doi:
3. Varma RS, Garg PK, Verma HN, Awasthi LP. Synthesis and antiviral activity of some 3-arylthiosemicarbazono-2-indolinones. Arch Pharm (Weinheim) . 1981; 314:918-922. doi:
4. Varma RS, Garg PK. Thin layer chromatography separation of some 3-arylthiosemicarbazono-2-indolinones. Z Ann Chem. 1981; 307:416. doi:
5. Varma RS, Garg PK. Antibacterial and antifungal activity of some new 3-arylglycyl hydrazono-2-indolinones. J Antibact Antifun Agents. 1981; 9:573-576. doi:
6. Varma RS, Garg PK. Reaction of 3-arylimino-2-indolinones with ρ-substituted phenylthiosemicarbazides. J Indian Chem Soc. 1981; 57:980-981. doi:
7. Varma RS, Garg PK. New 5-chloro-3-aryloxyacetylhydrazono-2-indolinones as antibacterial agents. J Antibact Antifun Agents. 1982; 10:195-196. doi:
8. Varma RS, Garg PK, Verma HN, Awasthi LP. Effect of some 5-chloro 3-aryl oxyacetylhydrazono-2-indolinones on Sunnhemp rosette virus. Indian Drugs. 1984; 21:512. doi:
9. Agrawal KC, Larroquette CA, Garg PK. Pharmacokinetic studies of amino acid analogs of 2-nitroimidazole, new hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1984; 10:1301-1305. doi: http://dx.doi.org/10.1016/0360-3016(84)90336-5
10. Lam LKT, Garg PK, Swanson SM, Pezzuto JM. Evaluation of the cytotoxic potential of catechols and quinines structurally related to butylated hydroxyanisole. J Pharm Sci. 1988; 77:393-395. doi:
11. Garg PK, Archer GE, Bigner DD, Zalutsky MR. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labeling. Appl Radiat Isot. 1989; 40:485-490. doi:
12. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab)2 fragments with the alpha-particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. ProcNatlAcadSci (U.S.A.) . 1989; 86:7149-7153. doi:
13. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE). Cancer Res. 1989; 49:5543-5549. doi:
14. Garg PK, Friedman H, Slade S, Bigner DD, Zalutsky MR. Astatine-211 labeled monoclonal antibody: a potential agent for radioimmunotherapy. NuclMedizinSuppl. 1989; 25:663-666. doi:
15. Garg PK, Slade S, Zalutsky MR, Harrison C. Labeling proteins using aryl iodide acylating agents: influence of metaversus para substitution on in vivo stability. Nucl Med Biol. 1989; 16:669-673. doi:
16. Garg PK, Harrison C, Zalutsky MR. Comparative tissue distribution of the alpha emitter 211 At and 131I labels of a monoclonal antibody and F(ab)2 fragment. Cancer Res. 1990; 50:3514-3520. doi:
17. Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. ActaRadiolSuppl. 1990; 374, 141-145. doi:
18. Lam LKT, Garg PK. Tumorigenicity of di-tert-butyl-substituted hydroxyl- quinine and hydroxyanisoles in the forestomach of Syrian golden hamsters. Carcinogenesis. 1991; 12:1341-1344. doi: 10.1093/carcin/12.7.1341
19. Garg S, Garg PK, Zalutsky MR. N-succinimidyl-5-(trialkylstannyl)-3-pyridine carboxylates: a new class of reagents for protein radiohalogenation. Bioconjug Chem. 1991; 2:50-56. doi:
20. Garg PK, Garg S, Zalutsky MR. Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. BioconjugChem. 1991; 2:44-49. doi:
21. Schuster JM, Garg PK, Bigner DD, Zalutsky MR. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE). Cancer Res. 1991; 51:4164-4169. doi:
22. Zalutsky MR, Garg PK, Johnson SH, Coleman RE. Fluorine- 18 antimyosin monoclonal antibody fragments: preliminary investigation in a canine myocardial infarct model. J Nucl Med. 1992; 33:575-580. doi:
23. Garg PK, DeGraff W, Garg S, Zalutsky MR, Mitchell JB. 4-Fluorobenzyl amine and phenylalanine methyl ester conjugates of 2-nitromidazole: synthesis and evaluation as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys. 1992; 23:593-596. doi: http://dx.doi.org/10.1016/0360-3016(92)90884-K
24. Garg PK, Garg S, Bigner DD, Zalutsky MR. Selective localization of an 18F-labeled Mel-14 monoclonal antibody F(ab)2 fragment in a subcutaneous human gliomaxenograft model. Cancer Res. 1992; 52:5054-5064. doi:
25. Garg PK, Garg S, Zalutsky MR. N-succinimidyl-4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. Nucl Med Biol. 1993; 20:379-387. doi:
26. Garg S, Garg PK, Zhao XG, et al. Radioiodination of MAb 81C6 and a fragment Mel-14(ab)2 using N-succinimidyl-5-(tri-n-butylstannyl) pyridine carboxylate. Nucl Med Biol. 1993; 20:835-842. doi:
27. Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan GV, Coleman RE. Measuring Astatine-211 distribution with SPECT. Phys Med Biol . 1993; 38:1121-1130. doi: 10.1088/0031-9155/38/8/010
28. Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidines. Nucl Med Biol. 1994; 21:97-103. doi: http://dx.doi.org/10.1016/0969-8051(94)90135-X
29. Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR. Positron emission tomographic images of osteosarcoma in dogs using an 18F-labeled monoclonal antibody Fab fragment. J Nucl Med. 1994; 35:1506-1513. doi:
30. Page RL, Garg PK, Vaidyanathan G, Zalutsky MR. Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab)2 fragment in normal dogs. Nucl Med Biol. 1994; 21:911-919. doi: http://dx.doi.org/10.1016/0969-8051(94)90079-5
31. Zalutsky MR, McLendon R, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994; 54:4719-4725. doi:
32. Garg PK, John CS, Zalutsky MR. Preparation and preliminary evaluations of 4-[211At]astato N-piperidinoethylbenzamide. Nucl Med Biol. 1995; 22:465-473. doi: http://dx.doi.org/10.1016/0969-8051(94)00134-6
33. Garg PK, Alston KL, Zalutsky MR. Catabolism of radioiodinated murine monoclonal antibody F(ab)2 fragment labeled using N-succinimidyl 3-iodobenzoate and iodogen. BioconjugChem. 1995; 6:493-501. doi:
34. Smellie WJB, Dean CJ, Sacks NPM, et al. Radioimmunotherapy of human breast cancer xenograft with monoclonal antibody ICR12 against c-erbB2p185: comparison of iodogen and N-succinimidyl 4-methyl 3-(tri-n-butylstannyl)benzoate. Cancer Res. 1996; 55:5842(s)-5846(s). doi:
35. Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR. Radioiodination of internalizing monoclonal antibodies using N-succinidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 1996; 56:4970-4979. doi:
36. Berry CR, Garg PK, DeGrado TR, et al. Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J Nucl Cardiology. 1996; 3:119-129. doi:
37. McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered [211At]astatide in B6C3F1 and Balb/c (nu/nu) mice: a long term survival study with histologic analysis. Int J RadiatOncolBiolPhy. 1996; 35:69-80. doi:
38. Zalutsky MR, Archer GE, Garg PK, Batra SK, Bigner DD. Chimeric antitenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol. 1996; 23:449-458. doi: http://dx.doi.org/10.1016/0969-8051(96)00021-2
39. Berry CR, Garg PK, Zalutsky MR, Coleman RE, DeGrado TR. Uptake and retention kinetics of para-[18F]fluorobenzylguanidine in the isolated rat heart. J Nucl Med. 1996; 37:2011-2016. doi:
40. Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of “α-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. BioconjugChem. 1996; 7:233-239. doi: 10.1021/bc960001
41. Tan PZ, Baldwin RM, Soufer R, Garg PK, Charney DS, Innis RB. A complete remote-control system for reliable preparation of [F-18]altanserin. Appl Radiat Isot. 1999; 50:923-927. doi: 10.1016/S0969-8043(98)00150-X
42. McNulty PH, Jagasia D, Ng CK, Garg PK, Whiting JM, Soufer S. Persistent changes in myocardial glucose metabolism during reperfusion of a limited-duration coronary artery occlusion in rats. Circulation. 2000; 101:917-922. doi: 10.1161/01.CIR.101.8.917
43. Van Dyck CH, Tan PZ, Baldwin RM, et al. PET quantification of 5-HT2A receptor in human brain: a constant infusion paradigm with [18F] Altanserin. J Nucl Med. 2000; 41:234-241. doi:
44. Van Dyck CH, Tan PZ, Baldwin RM, et al. Equilibrium modeling of 5-HT2A receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol. 2000; 27:715-722. doi: http://dx.doi.org/10.1016/S0969-8051(00)00160-8
45. Garg PK, Labree DC, Hoyte RM, Hochberg RB. 7-F-18fluoro 17-methyl 5- alphadihydroxytestosterone: a ligand for androgen mediated receptor mediated imaging of prostate cancer. Nucl Med Biol. 2001; 28:85-90. doi: http://dx.doi.org/10.1016/S0969-8051(00)00172-4
46. Staley JK, Van Dyck CH, Tan P, et al. Pharmacological characterization of F-18 deuteroaltanserin: a PET radiotracer for equilibrium imaging of serotonin-2A receptors. Nucl Med Biol. 2001; 28:271-279. doi: http://dx.doi.org/10.1016/S0969-8051(00)00212-2
47. Soares JC, Van Dyck CH, Tan P-Z, et al. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [F18]deuteroaltanserin. Psychiatr Res. 2001; 81-93. doi: http://dx.doi.org/10.1016/S0925-4927(01)00071-3
48. Berry CR, DeGrado TR, Nutter F, et al. Imaging of pheochromocytoma in dogs using para-[F-18]fluorobenzylguanidine. Vet Radiol Ultrasound. 2002; 43:183-186. doi:
49. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in post menopausal women. Am J Psychiatry. 2003; 160:1522-24. doi:
50. Bremner JD, Vythilingam M, Vermetten E, et al. MRI and PET studies of deficit in hippocampal structure and function in women with childhood abuse and posttraumatic stress disorder. Am J Psychiatry. 2003; 160:924-32. doi:
51. Chaley T, Baldwin RM, Neumeyer JL, et al. Radiosynthesis of F-18 N-3-(fluoropropyl)-2-β-(4 bromophenyl) nortropane and the regional brain uptake in non human primate using PET. Nucl Med Biol. 2004; 31:125-131. doi: http://dx.doi.org/10.1016/S0969-8051(03)00110-0
52. Garg S, Thopate SR, Minton RC, Black KW, Lynch A, and Garg PK. 3-Amino-4-(2-((4-[18F]fluorobenzyl)methyl amino)-methyl-phenylsulfanyl)-benzonitrile (FBASB): An F-18 fluorobenzyl analogue of DASB. Synthesis, in-vitro and in vivo biodistribution studies. Bioconjugate Chemistry. 2007; 18: 1612-1618 doi: 10.1021/bc070112g
53. Banks ML, Czoty PW, Gage HD, et al. Effects of Cocaine and MDMA Self-Administration on Serotonin Transporter Availability in Monkeys. Neuropsychopharmacology. 2008; 33: 219-25. doi: 10.1038/sj.npp.1301420
54. Garg S, Doke A, Black KW, and Garg PK. In vivo biodistribution of an androgen receptor avid PET imaging agent 7-α-fluoro-17 -methyl-5-dihydrotestosterone ([18F]FMDHT) in rats pre-treated with cetrorelix, a GnRH antagonist. Eur J Nucl Med Mol Imaging. 2008; 35: 379-85. doi: 10.1007/s00259-007-0610-3
55. Garg S, Lynch A, Minton RC, and Garg PK. A remote controlled system for the preparation of 7-α[18F]fluoro 17-α methyl 5-α dihydrotestosterone ([18F] FMDHT) using microwave. Appl. Rad Isotopes. 2008; 66: 612-618. doi: 10.1016/j.apradiso.2008.01.017.
56. Czoty PW, Riddick NV, Gage DH, et al. Effect of menstrual cycle phase on dopamine D2 receptor availability in female cynomolgus monkeys. Neuropsychopharmacology. 2009;34: 548-554. doi: 10.1038/npp.2008.3.
57. Riddick NV, Czoty PW, Gage HD, et al. Behavioral and neurobiological characteristics influencing social hierarchy formation in female cynomolgus monkeys. Neuroscience. 2009; 158: 1257-65. doi:
58. Garg S, Kothari K, Doke AK, Thopate SR, Garg, PK. Design, synthesis and preliminary evaluation of 4-[18F]fluoro N-(2-diethylaminoethyl)benzamide, [18F]-DAFBA: A novel potential PET imaging probe to image melanoma tumors. Bioconjugate Chemistry. 2009; 20, 583-590.
59. Clark PB, Plaza MJ, Kraas J, et al. Dual radiotracer analysis of cholinergic neuronal changes in prediabetic mouse pancreas. Diabetes TechnolTherap. 2009; 11: 107-111. doi: 10.1089/dia.2008.0024.
60. Clark PB, Kavanagh K, Gage HD, et al. Enhanced cholinergic response in pancreata of non-human primates with impaired glucose tolerance shown on [18F]-fluorobenzyltrozamicol positron emission tomography. Diabetes TechnolTherap. 2009; 11: 451-455. doi: 10.1089/dia.2008.0113.
61. Rose JE, Mukhin AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and non-dependent smokers: a PET study with 11C-nicotine cigarettes. ProcNatlAcad Sci. 2010; 107: 5190 - 5195. doi: 10.1073/pnas.0909184107.
62. Nader MA, Nader SH, Czoty PW, et al. Social Dominance in female monkeys: Dopamine receptor function and cocaine reinforcement. Biological Psychiatry. 2012; 72: 414-421. doi: 10.1016/j.biopsych.2012.03.002.
63. Gould RW, Garg PK, Garg SG, Nader MA. Effects of nicotinic acetylcholine receptor agonist on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology. 2013; 64: 479-488. doi: 10.1016/j.neuropharm.2012.08.004.
64. Czoty PW, Gaze HD, Garg PK, Garg S, Nader MA. Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys. Psychopharmacology (Berl). 2013; doi: 10.1007/s00213-013-3274-7
65. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F-18 AV-45) PET to assess amyloid burden in Alzheimers disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013; 9(0): S72–S83. doi: 10.1016/j.jalz.2012.10.007.
66. Garg PK, Batra SK, Garg S. Role of Molecular Imaging in Oncology. Cancer Stud Mol Med Open J. 2014;1(1): e1-e7. doi: 10.17140/CSMMOJ-1-e001